Abstract: The technology relates in part to binding molecules that specifically bind to a polypeptide that is the Isoform 2 of mesotheiin, or that specifically bind to an antigenic determinant (epitope) of the isoform 2 of mesotheiin, or that specifically bind to polypeptides containing an antigenic determinant (epitope) of the isoform 2 of mesotheiin, chimeric PD1 receptors that bind to PD ligands such as PDLs, to polynucleotides including vectors that encode such binding molecules, to ceils presenting such binding molecules and to methods of making such cells, to humanized forms of the binding molecules, and to methods of using such binding molecules, such as for treating cancers (e.g., ovarian cancers and mesotheliomas), including cancers in which the Isoform 2 of mesotheiin is specifically expressed and/or upregulated relative to normal tissues.

Abstract: The technology relates in part to binding molecules that specifically bind to a polypeptide that is the Isoform 2 of mesothelin, or that specifically bind to an antigenic determinant (epitope) of the isoform 2 of mesothelin, or that specifically bind to polypeptides containing an antigenic determinant (epitope) of the isoform 2 of mesothelin, chimeric PD1 receptors that bind to PD ligands such as PDLs, to polynucleotides including vectors that encode such binding molecules, to ceils presenting such binding molecules and to methods of making such cells, to humanized forms of the binding molecules, and to methods of using such binding molecules, such as for treating cancers (e.g., ovarian cancers and mesotheliomas), including cancers in which the Isoform 2 of mesothelin is specifically expressed and/or upregulated relative to normal tissues.

Abstract: The technology relates in part to methods and systems for the identification of disease-associated transcript isoforms and peptides. In certain aspects, the technology relates to methods and systems for the identification of transcript isoforms and peptides preferentially expressed in tumor cells.

Abstract: Compositions for reducing skin aging resulting from oxidative stress and/or photodamage are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: A beverage dispensing system and method include a beverage dispensing device that has a processor and a memory accessible to the processor. The memory stores instructions that when executed by the processor implement a method that includes receiving a beverage selection, and comparing the beverage selection to predefined controls. The selected beverage is dispensed in response to the comparison.

Abstract: Compositions for reducing skin aging resulting from oxidative stress and/or photodamage are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: Compositions for reducing skin aging resulting from oxidative stress and/or photodamage are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: Compositions for reducing skin aging resulting from oxidative stress and/or photodamage are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.